DK2146733T3 - Treatment of leaky or damaged tight junctions and enhancing extracellular matrix - Google Patents

Treatment of leaky or damaged tight junctions and enhancing extracellular matrix Download PDF

Info

Publication number
DK2146733T3
DK2146733T3 DK08732273.1T DK08732273T DK2146733T3 DK 2146733 T3 DK2146733 T3 DK 2146733T3 DK 08732273 T DK08732273 T DK 08732273T DK 2146733 T3 DK2146733 T3 DK 2146733T3
Authority
DK
Denmark
Prior art keywords
leaky
treatment
extracellular matrix
tight junctions
enhancing extracellular
Prior art date
Application number
DK08732273.1T
Other languages
Danish (da)
English (en)
Inventor
Stephen Richard Kelly
Terrence W Norchi
Rutledge Ellis-Behnke
Original Assignee
Arch Biosurgery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Biosurgery Inc filed Critical Arch Biosurgery Inc
Application granted granted Critical
Publication of DK2146733T3 publication Critical patent/DK2146733T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
DK08732273.1T 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix DK2146733T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89487207P 2007-03-14 2007-03-14
PCT/US2008/057104 WO2008113030A2 (en) 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Publications (1)

Publication Number Publication Date
DK2146733T3 true DK2146733T3 (da) 2021-01-11

Family

ID=39462068

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08732273.1T DK2146733T3 (da) 2007-03-14 2008-03-14 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix

Country Status (7)

Country Link
US (2) US9415084B2 (OSRAM)
EP (1) EP2146733B1 (OSRAM)
JP (4) JP2010521495A (OSRAM)
CA (1) CA2680824C (OSRAM)
DK (1) DK2146733T3 (OSRAM)
ES (1) ES2854674T3 (OSRAM)
WO (1) WO2008113030A2 (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US8143042B2 (en) 2006-01-12 2012-03-27 Massachusetts Institute Of Technology Biodegradable elastomers
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101472620A (zh) 2006-04-25 2009-07-01 麻省理工学院 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
WO2009033781A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100061487A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 펩티드 ｙｇｌｆ 및 ｋｖｌｐｖｐｑ와의 배합물의 치료적 용도
EP2345433B1 (en) * 2008-10-06 2017-03-01 3-D Matrix, Ltd. Tissue plug
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
US9084752B2 (en) * 2009-12-14 2015-07-21 The University Of Hong Kong Compositions and methods for controlling proliferation and differentiation of cells
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US20110143993A1 (en) * 2009-12-15 2011-06-16 The Brigham And Women's Hospital, Inc. Endothelial basement membrane targeting peptide ligands
US8741833B2 (en) * 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
WO2012008967A1 (en) * 2010-07-16 2012-01-19 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
CN103298507B (zh) * 2010-10-07 2015-08-26 麻省理工学院 采用线性洛仑兹力致动的无针射流注射系统递送固体和/或流体
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
US8663932B2 (en) 2010-12-21 2014-03-04 Leidos, Inc. Methods and compositions for wound treatment
JP6389170B2 (ja) 2012-07-06 2018-09-12 スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． ペプチド溶液のためのフィル−フィニッシュ過程
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
US9241891B2 (en) * 2012-10-30 2016-01-26 The Procter & Gamble Company Personal care compositions comprising self-assembling peptides
US9981059B2 (en) * 2013-03-30 2018-05-29 Glytech, Inc. Sugar chain-polypeptide complex
CN105658252A (zh) * 2013-08-22 2016-06-08 阿奇生物外科有限公司 用于控制流体移动的可植入网状物
AU2014327234B2 (en) 2013-09-25 2019-02-21 Credentis Ag Dental care product for tooth whitening
EP2853256A1 (en) 2013-09-25 2015-04-01 Credentis AG Dental care product for tooth whitening
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
EP3124058A4 (en) * 2014-03-28 2017-11-29 Otsuka Chemical Co., Ltd. Hemostatic pharmaceutical composition
US11298397B2 (en) 2015-12-18 2022-04-12 3-D Matrix, Ltd. Hemostatic composition and hemostatic method using hemostatic composition
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
EP3248590A1 (en) 2016-05-24 2017-11-29 Credentis AG Personal dental care product for caries treatment
EP3248591A1 (en) 2016-05-24 2017-11-29 Credentis AG Method and product for caries treatment
US20190060506A1 (en) * 2017-08-22 2019-02-28 The Board Of Trustees Of The Leland Stanford Junior University Elafin Incorporated Biomaterials for the Treatment of Chronic Tissue Ulcers
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery
JPWO2019139126A1 (ja) * 2018-01-11 2021-04-08 国立大学法人 東京大学 Ｎｔｃｐ阻害剤
EP3768296B1 (en) 2018-03-23 2023-09-06 Arch Biosurgery, Inc. Sap and peptidomimetics for treatment of eye disease
CA3094984A1 (en) 2018-03-23 2019-09-26 Arch Biosurgery, Inc. Sap and peptidomimetic compositions for reducing symptoms of inflammation
WO2020071527A1 (ja) * 2018-10-05 2020-04-09 学校法人 久留米大学 腸管における潰瘍または瘻孔の治療または予防のための医薬組成物
EP3952973B1 (en) 2019-06-13 2023-06-07 Hollister Incorporated Reusable urinary catheter products
AU2020304005B2 (en) 2019-06-25 2025-12-04 Hollister Incorporated Reusable urinary catheter products
EP3831360A1 (en) 2019-12-04 2021-06-09 Credentis AG Personal dental care product for preventing demineralisation
CN111116717B (zh) * 2020-01-03 2021-10-29 中国科学院大学温州研究院(温州生物材料与工程研究所) 含有n-甲基-d-葡糖胺单元的糖肽水凝胶、制备方法及其应用
EP4090350A1 (en) 2020-01-13 2022-11-23 Arch Biosurgery, Inc. Self-assembling peptide gel formulation and methods of use
US11154470B1 (en) 2020-07-31 2021-10-26 vVardis AG Anti-inflammatory and senolytic dental care product with tooth whitening characteristics
JP2024506048A (ja) * 2021-02-10 2024-02-08 株式会社スリー・ディー・マトリックス 特異的な自己組織化ペプチドｒａｄａ１６を含む、炎症性腸疾患などの下部消化管疾患を治療又は予防するための医薬組成物
CN120344547A (zh) * 2022-12-16 2025-07-18 东亚合成株式会社 合成肽和构建体
CN116789854B (zh) * 2023-06-08 2024-04-02 东北农业大学 兼具细菌捕获与抑菌功能的纳米抗菌肽及制备方法和应用
WO2025226888A1 (en) * 2024-04-26 2025-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ecm-derived injectable embolic for permanent treatment of cerebral aneurysms

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4211227A (en) 1978-07-03 1980-07-08 The Kendall Company Surgical sponge material
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4636208A (en) 1984-10-05 1987-01-13 Ewald Rath Surgical sponge
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5019646A (en) 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JP2528602B2 (ja) 1989-12-04 1996-08-28 ケンゼー・ナッシュ・コーポレーション 開口部を封止するためのプラグ装置
US5180375A (en) 1991-05-02 1993-01-19 Feibus Miriam H Woven surgical drain and woven surgical sponge
US5222974A (en) 1991-11-08 1993-06-29 Kensey Nash Corporation Hemostatic puncture closure system and method of use
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5645565A (en) 1995-06-13 1997-07-08 Ethicon Endo-Surgery, Inc. Surgical plug
US6368877B1 (en) 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US6235340B1 (en) 1998-04-10 2001-05-22 Massachusetts Institute Of Technology Biopolymer-resistant coatings
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
WO2000063079A1 (en) 1999-04-15 2000-10-26 Ultracell Medical Technologies Of Connecticut, Inc. Method for producing surgical sponge device and product thereof
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US6953659B2 (en) 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of nucleic acids
US6953656B2 (en) 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of polypeptides
US6846319B2 (en) 2000-12-14 2005-01-25 Core Medical, Inc. Devices for sealing openings through tissue and apparatus and methods for delivering them
ATE419333T1 (de) 2001-02-06 2009-01-15 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2003052117A2 (en) 2001-09-19 2003-06-26 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
WO2003084980A2 (en) 2002-04-02 2003-10-16 Northwestern University Peptide amphiphile solutions and self assembled peptide nanofiber networks
WO2003096972A2 (en) 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
CA2387257C (en) 2002-05-23 2009-07-28 Suncor Energy Inc. Static deaeration conditioner for processing of bitumen froth
GB0216286D0 (en) 2002-07-15 2002-08-21 Univ Leeds Network
JP2005534697A (ja) 2002-08-06 2005-11-17 エピックス ファーマシューティカルズ， インコーポレイテッド ペプチド凝集体
DK1636250T3 (en) 2003-06-25 2016-02-22 Massachusetts Inst Technology SELF-ORGANIZING PEPTIDES, CONTAINING MODIFICATIONS, AND APPLICATIONS THEREOF
US7713923B2 (en) * 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7846891B2 (en) 2003-10-17 2010-12-07 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
GB0413346D0 (en) 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
EP4023240A1 (en) 2004-07-06 2022-07-06 3D Matrix, Inc. Purified amphiphilic peptide compositions and uses thereof
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
US8039258B2 (en) 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
US7399831B2 (en) * 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
CN101472620A (zh) 2006-04-25 2009-07-01 麻省理工学院 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法
US20070287741A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
US20120085262A1 (en) 2010-08-26 2012-04-12 Freudenberg Forschungsdienste Kg Production of Highly Concentrated Solutions of Self-Assembling Proteins

Also Published As

Publication number Publication date
CA2680824C (en) 2018-06-26
JP2017105833A (ja) 2017-06-15
JP5860437B2 (ja) 2016-02-16
US20160324918A1 (en) 2016-11-10
EP2146733A2 (en) 2010-01-27
EP2146733B1 (en) 2020-11-25
WO2008113030A2 (en) 2008-09-18
CA2680824A1 (en) 2008-09-18
JP2010521495A (ja) 2010-06-24
JP2015028086A (ja) 2015-02-12
JP6112621B2 (ja) 2017-04-12
WO2008113030A3 (en) 2009-04-02
ES2854674T3 (es) 2021-09-22
US9415084B2 (en) 2016-08-16
JP2013177467A (ja) 2013-09-09
US20080274979A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
DK2146733T3 (da) Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
EP2180897A4 (en) TYROSINASE INHIBITORY PEPTIDES AND USES THEREOF
BRPI0820882A2 (pt) Dispositivos e métodos de estimulação de dermátomo
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
BRPI0807525A2 (pt) Dispositivo endo-cirúrgico e método
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
DK2281006T3 (da) Tværbindingsmidler og anvendelser deraf
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK3058875T3 (da) System til kosmetisk behandling og billedoptagelse
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2220320T3 (da) Forseglet enhed og mellemstykke
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
DK2192933T3 (da) Materialer til oftalmologisk og ortorhinolaryngologisk anordning
EP2142572A4 (en) TGFP CAP PEPTIDE AND APPLICATIONS THEREOF
BRPI0816907A2 (pt) Método e dispositivo
DK2310357T3 (da) Kaliumionkanalmodulatorer og anvendelser deraf
FI20075881A0 (fi) Lääketieteellinen väline ja sen käyttö
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
BRPI0816789A2 (pt) Goji e inflamação
BRPI0819488A2 (pt) Dispositivos de terapia e gel térmico